The bulls are sharpening their horns in sweet anticipation of Vanda Pharmaceuticals' (NASDAQ:VNDA) upcoming Advisory Committee Meeting with the FDA for tasimelteon's New Drug Application (NDA). Tasimelteon is a circadian regulator in development as an indication for Non-24Hr disorder in the totally blind.
Last December, Vanda reported positive Phase III data for tasimelteon, causing the stock to surge 166% year-to-date. Adding fuel to the fire, the FDA recently agreed to bestow upon tasimelteon a highly coveted "Priority Review". The drug is thus set for an Advisory Committee hullabaloo on November 14th, with a target PDUFA date of January 31, 2014. With peak sales projected to top $500 M per year for a company with a sub $300...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|